drugset / Trial / NCT05355935

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

NCT05355935

Phase 1 Completed 48 enrolled Insmed Incorporated
RandomizedCrossoverQuadruple-blindTreatment

Summary

The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.

Timeline

Start
2022-04-27
Primary completion
2022-10-07
Completion
2022-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Brensocatib Small molecule Oral
Subject Moxifloxacin Small molecule Oral

Indications

No indication recorded.